Suppr超能文献

直肠癌放疗、淋巴结检出与生存时间的关系。

Timing of radiation therapy, lymph node retrieval, and survival in rectal cancer.

机构信息

Department of Medicine, University of California Irvine, Irvine, California, USA.

出版信息

Dis Colon Rectum. 2011 May;54(5):526-34. doi: 10.1007/DCR.0b013e31820939fb.

Abstract

BACKGROUND

Lymph node retrieval is an independent prognostic factor for survival in rectal cancer. Preoperative radiotherapy has been shown to impact the number of lymph nodes retrieved.

OBJECTIVE

This study aimed to analyze colorectal cancer-specific mortality and overall mortality associated with the number of lymph nodes retrieved in relation to use and timing of radiotherapy.

DESIGN

This study was designed as a retrospective analysis.

SETTINGS

Analysis of the California Cancer Registry was conducted.

PATIENTS

Patients with rectal cancer from 1994 to 2006 with a follow-up until January 2008 were included.

MAIN OUTCOME MEASURES

The number of lymph nodes (1-3, 4-6, 7-11, ≥ 12) stratified by stage (I, II, and III) was analyzed based on radiotherapy status (no radiotherapy, preoperative radiotherapy, and postoperative radiotherapy). Multivariate colorectal cancer-specific survival and overall mortality analyses were performed using Cox proportional-hazard ratios.

RESULTS

A total of 17,670 incident cases of stage I, II, and III rectal cancer were identified. The number of lymph nodes retrieved in cases receiving preoperative radiotherapy was lower than others. In stage II cases receiving preoperative radiotherapy, retrieval of 7 to 11 lymph nodes (compared with 0 lymph nodes retrieved as a reference) reached the nadir of colorectal cancer-specific mortality benefit (HR = 0.39, 95% CI, 0.28-0.56) and overall mortality (HR = 0.62, 95% CI, 0.48-0.80). In stage II cases with no radiotherapy or postoperative radiotherapy, retrieval of ≥ 12 lymph nodes remained the strongest prognosticator of colorectal cancer-specific mortality (HR = 0.34, 95% CI, 0.25-0.46; HR = 0.36, 95% CI, 0.24-0.53 respectively).

LIMITATIONS

: The California Cancer Registry does not include radiation dose and duration, chemotherapy type and dosage, margin status and surgeon characteristics, and stated reasons for lower number of lymph nodes retrieved or patient-related factors. In addition, no central pathology laboratory was used.

CONCLUSIONS

In stage II rectal cancer cases receiving preoperative radiotherapy vs either postoperative or no radiotherapy, a lower threshold of lymph node retrieval may be sufficient to evaluate prognosis and to guide further therapy.

摘要

背景

淋巴结检出数量是直肠癌患者生存的独立预后因素。术前放疗已被证明会影响淋巴结检出数量。

目的

本研究旨在分析与放疗的应用和时机相关的淋巴结检出数量与结直肠癌特异性死亡率和总死亡率之间的关系。

设计

本研究设计为回顾性分析。

设置

对加利福尼亚癌症登记处进行了分析。

患者

纳入了 1994 年至 2006 年期间患有直肠癌且随访至 2008 年 1 月的患者。

主要观察指标

根据放疗情况(无放疗、术前放疗和术后放疗)对各期(I 期、II 期和 III 期)的淋巴结数量(1-3、4-6、7-11、≥12)进行分层。使用 Cox 比例风险比进行多变量结直肠癌特异性生存和总死亡率分析。

结果

共确定了 17670 例 I 期、II 期和 III 期直肠癌的首发病例。接受术前放疗的病例中淋巴结检出数量较低。在接受术前放疗的 II 期病例中,检出 7 至 11 个淋巴结(与以检出 0 个淋巴结为参考相比)达到了结直肠癌特异性死亡率获益的峰值(HR=0.39,95%CI,0.28-0.56)和总死亡率(HR=0.62,95%CI,0.48-0.80)。在无放疗或术后放疗的 II 期病例中,检出≥12 个淋巴结仍然是结直肠癌特异性死亡率的最强预后因素(HR=0.34,95%CI,0.25-0.46;HR=0.36,95%CI,0.24-0.53)。

局限性

加利福尼亚癌症登记处未包括辐射剂量和持续时间、化疗类型和剂量、切缘状态和外科医生特征以及检出淋巴结数量较少的原因或患者相关因素。此外,未使用中央病理实验室。

结论

在接受术前放疗的 II 期直肠癌病例中,与术后放疗或无放疗相比,较低的淋巴结检出阈值可能足以评估预后并指导进一步治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验